Participants
psychiatric, neurological diseases
MIGRAINE HEADACHES, NEUROLOGICAL DISEASE, BLIND
Healthy, right-handed male and female participants (18–45 years) were recruited in a double blind, placebo-controlled, randomized, single dose, parallel-group study with three treatment conditions (placebo-placebo, placebo-ketamine, lamotrigine-ketamine). Exclusion criteria were a history of or current psychiatric conditions, as determined by the SCID-5-CV at screening, a positive drug screen, alcohol or substance dependence within the last 12 months, prescribed psychotropic medication within 28 days prior to screening and non-prescription medication within 48 h prior to treatment visit. Further exclusion criteria were a history of relevant neurological diseases, migraine headaches, relevant medical condition, MRI exclusion criteria, and pregnancy. All participants gave written consent to participate in the study, which was approved by the local ethics committee and registered at ClinicalTrials.gov (NCT04156035).